Fairvalue-Calculator Fairvalue-Calculator
EN DE

Solborn, Inc (035610) Fair Value & Analysis

Industrials · KR · Market cap 94.3B KRW

Price3,425 KRW
Fair Value6,850 KRW
Upside+100.0%
Quality80/100
Evidence: Medium Range 5,138 KRW – 8,563 KRW

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Solborn, Inc (035610) currently trades at 3,425 KRW, while our model-based Fair Value estimate is 6,850 KRW — implying the stock looks roughly 100.0% undervalued today. We read business quality at 80/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Solborn, Inc., an investment holding company, engages in the manufacturing and sales of medical equipment in South Korea. The company engages in the PACS and S/W manufacturing, sales, and maintenance; medical device H/W manufacturing, wholesale, and maintenance. It is also involved in provision of newspaper issuance and online information services. In addition, the company invests in small and medium-sized enterprises and venture companies. Further, it engages in golf related business and real estate leasing business. The company was formerly known as Serome Technology, Inc. Solborn, Inc. was founded in 1994 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Solborn, Inc (035610) undervalued?
As of Jun 26, 2026, our model estimates a fair value of 6,850 KRW versus a price of 3,425 KRW — about +100% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 035610?
Our 21-model fair value for Solborn, Inc is 6,850 KRW (as of Jun 26, 2026), built from audited fundamentals. The current price is 3,425 KRW.
What is the quality score of 035610?
Solborn, Inc has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.